TLQP-21 (TFA)-5 mg

Description

TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA activates C3aR1 to induce an increase of intracellular Ca2+. TLQP-21 TFA is used for the research in regulation of nociception and other relevant physiologic functions[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Metabolism-protein/nucleotide metabolism–C109H171F3N40O28—-[1]Elena Bresciani , et al. TLQP-21, A VGF-Derived Peptide Endowed of Endocrine and Extraendocrine Properties: Focus on In Vitro Calcium Signaling. Int J Mol Sci. 2019 Dec 24;21(1):130.|[2]Cheryl Cero, et al. The TLQP-21 Peptide Activates the G-protein-coupled Receptor C3aR1 via a Folding-Upon-Binding Mechanism. ructure. 2014 Dec 2;22(12):1744-1753.—-2546.77–99.90–O=C(N1[C@@H](CCC1)C(N[C@@H](C)C(N[C@H](C(O)=O)CCCNC(N)=N)=O)=O)[C@H]2N(CCC2)C([C@H](CC(C)C)NC([C@H](C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CO)NC([C@H](CO)NC([C@H](C)NC([C@H]3N(CCC3)C([C@H]4N(CCC4)C([C@H](CCC(N)=O)NC([C@H](CC(C)C)NC([C@@H](N)[C@H](O)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC5=CN=CN5)=O)CC6=CC=CC=C6)=O)CC7=CN=CN7)=O)CC8=CN=CN8)=O)=O)=O.O=C(O)C(F)(F)F–Endocrinology; Neurological Disease–H2O : 50 mg/mL (ultrasonic)–Complement System—-Immunology/Inflammation–Peptides